Abstract
Malignant gliomas, the most common malignant primary brain tumors, have a deleterious clinical prognosis of approximately 12 months in unselected series. The resistance against antineoplastic therapy is apparently not only associated with a high proliferative potential, marked antiapoptotic resistance and high migratory capacity. Effective mechanisms to escape the immune response of the organism and an intense neoangiogenesis also contribute to the aggressive growth of these neoplasms. In addition to a number of molecular mechanisms, the group of glycohydrate-binding galectins seems to contribute to the aggressive growth of malignant gliomas. Galectin-1, -3, -4 and -8 have been shown to be overexpressed in malignant gliomas. Galectin-1 is known to be involved in glioma cell migration and possibly also in proliferation. In this review, various aspects of glioma biology and their therapeutic relevance is discussed. The role of galectins in apoptosis-resistance, immune response and angiogenesis is discussed and explained why these molecules are interesting targets of glioma therapy.
Keywords: Galectin, glioma, glioblastoma, therapy, angiogenesis, apoptosis, immune response, brain tumors, antineoplastic therapy, antiapoptotic resistance, apoptosis-resistance, glioma therapy
Current Pharmaceutical Biotechnology
Title:Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options
Volume: 13 Issue: 11
Author(s): Herwig M. Strik, Malgorzata Kolodziej, Wolfgang Oertel and Jorg Basecke
Affiliation:
Keywords: Galectin, glioma, glioblastoma, therapy, angiogenesis, apoptosis, immune response, brain tumors, antineoplastic therapy, antiapoptotic resistance, apoptosis-resistance, glioma therapy
Abstract: Malignant gliomas, the most common malignant primary brain tumors, have a deleterious clinical prognosis of approximately 12 months in unselected series. The resistance against antineoplastic therapy is apparently not only associated with a high proliferative potential, marked antiapoptotic resistance and high migratory capacity. Effective mechanisms to escape the immune response of the organism and an intense neoangiogenesis also contribute to the aggressive growth of these neoplasms. In addition to a number of molecular mechanisms, the group of glycohydrate-binding galectins seems to contribute to the aggressive growth of malignant gliomas. Galectin-1, -3, -4 and -8 have been shown to be overexpressed in malignant gliomas. Galectin-1 is known to be involved in glioma cell migration and possibly also in proliferation. In this review, various aspects of glioma biology and their therapeutic relevance is discussed. The role of galectins in apoptosis-resistance, immune response and angiogenesis is discussed and explained why these molecules are interesting targets of glioma therapy.
Export Options
About this article
Cite this article as:
M. Strik Herwig, Kolodziej Malgorzata, Oertel Wolfgang and Basecke Jorg, Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802502051
DOI https://dx.doi.org/10.2174/138920112802502051 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets MicroRNA-490-5P Targets CCND1 to Suppress Cellular Proliferation in Glioma Cells and Tissue Through Cell Cycle Arrest
Current Neurovascular Research Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs as a New a Approach
Letters in Drug Design & Discovery CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology